SUCLG2 is estimated to be a biomarker candidate that can effectively differentiate between follicular adenoma and carcinoma with 75% sensitivity and 80% specificity, depending on a specific cutoff score extrapolated from the intensity and percentage of immunohistochemistry (IHC) staining [125]. Here, SUCLG2 is linked to follicular thyroid adenoma.